No label defined (Q3069477)

From EU Knowledge Graph
Revision as of 11:59, 16 August 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): The aim of the project is to develop a development platform for antiviral antibody candidates for medicinal products. The project will develop technologies for the development and production of antibodies based on secretory immunoglobulin A. In order to validate the novel approach, animal testing shall be carried out on antibodies against SARS-CoV-2 developed by the applicant, leading to secretory immunoglobulin A antibody isotype., translated_s...)
Jump to navigation Jump to search
Project Q3069477 in Estonia
Language Label Description Also known as
English
No label defined
Project Q3069477 in Estonia

    Statements

    0 references
    2,968,871.71 Euro
    0 references
    3,718,589.64 Euro
    0 references
    79.84 percent
    0 references
    1 February 2021
    0 references
    31 December 2023
    0 references
    Icosagen Cell Factory OÜ
    0 references
    61713
    0 references
    Projekti eesmärk on välja töötada viirusvastastel antikehadel pōhinev ravimikandidaatide arendusplatvorm. Projekti käigus arendatakse välja tehnoloogiad sekretoorse immunoglobuliin A põhiste antikehade arendamiseks ja tootmiseks. Uudse lähenemise valideerimiseks viiakse läbi loomkatsetused taotleja arendatud SARS-CoV-2 vastaste antikehadega, mis pōhinevad sekretoorse immunoglobuliin A antikeha isotüübil. (Estonian)
    0 references
    The aim of the project is to develop a development platform for antiviral antibody candidates for medicinal products. The project will develop technologies for the development and production of antibodies based on secretory immunoglobulin A. In order to validate the novel approach, animal testing shall be carried out on antibodies against SARS-CoV-2 developed by the applicant, leading to secretory immunoglobulin A antibody isotype. (English)
    16 August 2021
    0 references

    Identifiers

    2014-2020.4.02.21-0314
    0 references